In order to determine whether doses of cyclosporine and methylprednisolone used for prophylaxis and therapy of acute graft-versus-host disease (GVHD) have any influence on relapse and survival following allogeneic bone marrow transplantation (BMT), we studied 176 adult patients with hematologic malignancies, who underwent a first allogeneic transplant from an HLAidentical sibling donor. Two methods of management of acute GVHD used in two different centers were compared: group I included 62 patients who had 'standard' management of GVHD including prophylaxis with 1-3 mg/kg/day of cyclosporine and treatment with 2 mg/kg/day of methylprednisolone when acute GVHD developed; group II included 114 patients who received 'intensive' management of GVHD including prophylaxis with 5 mg/kg/day of cyclosporine and treatment with high-dose methylprednisolone (8-20 mg/kg/day for 3 days) at the onset of GVHD. The overall incidence of GVHD was the same in both groups. However, acute GVHD was more severe in group I than in group II (P Ͻ 0.0001), with consequently less resolution of GVHD after treatment in group I (61%) than in group II (80%) (P = 0.06). Overall survival and disease-free survival (DFS) did not differ between the two groups. However, actuarial risk of disease relapse was significantly higher in group II than in group I (36% vs 17%, P = 0.02). In a multivariate analysis taking into account known factors influencing GVHD and relapse, only type of GVHD management and age were significantly predictive for the occurrence of GVHD, while only type of GVHD management and pathology other than chronic myeloid leukemia (CML) were predictive for relapse. This study demonstrates that intensity of GVHD prophylaxis and therapy can influence the graft-versusleukemia effect by decreasing severity of GVHD but at the price of increasing relapse rate post transplant.
Graft-versus-host disease (GVHD) remains one of the major complications of allogeneic bone marrow transplantation (BMT). It occurs, despite prophylaxis, in 30-50% of patients transplanted from HLA-identical sibling donors and in 50-80% of patients transplanted from HLA-matched unrelated donors.
1,2 Acute GVHD is generally classified into four grades according to the Seattle criteria. 3 Morbidity and mortality of acute GVHD are related to primary immune dysfunction inherent to the disease itself as well as to the immunosuppressive effects of the therapy used. Long-term survival in patients developing severe (grades III-IV) acute GVHD has generally been less than 30%. 4, 5 Despite advances in the understanding of acute GVHD 6 and acute GVHD prophylaxis, 1, 7 the primary treatment of established disease has shown little improvement. Steroids remain the main therapy, alone or in association with antithymocyte globulin (ATG), cyclosporine (CsA) or monoclonal antibodies (MoAb). 8 Dose intensification or combination of agents may increase acute GVHD response to therapy, without necessarily improving survival, due to complications related to immunosuppression. In addition, decreasing acute GVHD may increase relapse rate post transplant. 9 Our study was performed to compare standard management of GVHD including CsA prophylaxis and corticosteroid therapy with an intensified management, using higher doses of the same drugs, and considered incidence and severity of GVHD, survival, disease-free survival (DFS) and relapse post transplant in patients undergoing allogeneic BMT from HLA-identical siblings.
Patients and methods

Patient selection criteria
We retrospectively reviewed files of adult patients (Ͼ15 years), who received a first non-T-depleted bone marrow transplant from an HLA-identical sibling donor in two centers (Grenoble = group I and Lyon = group II). GVHD prophylaxis was with CsA and methotrexate between December 1985 when CsA was first introduced, and August 1992 which was the date of changing the GVHD prophylaxis policy in the two centers. Only patients who survived more than 30 days post transplant and were therefore evalu-able for the occurrence of acute GVHD were included in the analysis.
Pretransplant characteristics of the two groups
One hundred and seventy-six patients satisfied the criteria for inclusion in the analysis: 62 in group I, representing 54% of patients allografted in center I during the study period, and 114 in group II, representing 57% of patients allografted in center II during the same period.
The patient population comprised 110 males and 66 females with a median age of 36 years (range: 16-58 years). Age and sex of patients and frequency of donorrecipient sex mismatch were similar in the two groups (Table 1) . However, groups significantly differed in diagnosis pretransplant, with more acute leukemias in group II compared to group I (P = 0.006), delay from diagnosis to transplant, with earlier transplants in group II (P = 0.009), status of disease pretransplant, with more diseases in complete remission and chronic myeloid leukemia in chronic phase in group II (P = 0.04) and conditioning regimen, with more TBI containing regimens in group I (P = 0.0002). Thirty-six percent of patients had a diagnosis other than acute or chronic myeloid leukemia comprising non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia and MDS. All patients were managed in laminar air flow rooms and received antimicrobials for gastrointestinal decontamination.
GVHD prophylaxis and therapy
In both groups of patients, CsA was used with methotrexate. 10 Two different approaches to GVHD prophylaxis and therapy were used in the two groups during the time of analysis. In group I, 62 patients received 'standard' prophylaxis and therapy of GVHD: prophylactic CsA at a dose of In group II, 114 patients received intensive prophylaxis and therapy of GVHD. CsA was given at 5 mg/kg/day i.v. unless nephrotoxicity developed: CsA was stopped when the serum creatinine exceeded 120 mmol/l and resumed at two-thirds of the initial dose upon normalization of serum creatinine. When acute GVHD developed, all patients received high-dose MP (8-20 mg/kg/day) for 3 days, which was repeated once if GVHD persisted or reappeared, then 2 mg/kg/day MP. Steroids were gradually tapered in the two groups.
There were no differences between the two centers apart from in the management of GVHD. Use of antibiotics, transfusions, and parenteral nutrition were all similar, as were strategies for CMV prophylaxis and chronic GVHD management. The two centers treated all patients with grade I acute GVHD. For some patients, a diagnosis of acute GVHD was confirmed by biopsy before treatment.
Criteria of evaluation
Acute GVHD was classified according to the Seattle criteria. 3 Response to GVHD therapy was classified as complete, which corresponded to resolution of GVHD in all evaluable organs involved with no subsequent additional treatment given for acute GVHD. Partial response was defined in two ways: as improvement in at least one evaluable organ without deterioration in others, or as resolution of GVHD in all evaluable organs with requirement for additional treatment because of anomalies persisting at a non-evaluable site. No response was defined as deterioration in at least one evaluable organ without improvement in others, or absence of any difference sufficient to meet minimal criteria for improvement, or deterioration in any evaluable organ after treatment. 10 Chronic GVHD was classified according to Seattle criteria. 11 
Statistical analysis
Comparative analysis of the two modes of GVHD management was carried out on an 'intention to treat' basis determined according to the center in which transplantation took place. The following parameters were analyzed for potential prognostic significance for occurrence and severity of GVHD, relapse, DFS and overall survival: age of patient, sex of patient and donor, indication for BMT (type and stage of underlying pathology), delay from diagnosis to BMT, use of TBI in conditioning and group of GVH management. In addition, the influence of occurrence and severity of GVHD on relapse and survival was evaluated.
Discrete variables were compared using Yate's corrected 2 , and 95% confidence intervals (CI) on proportions were calculated using the exact binomial formula. Continuous variables were compared by standard analysis of variance. Relapse, DFS and survival probabilities were calculated using the Kaplan and Meier product-limit estimate method, and their 95% symmetrical CI limit was calculated according to Greenwood's method. Survival curves were compared using the log-rank test. Prognostic factors for the occurrence of GVHD were studied using stepwise multiple logistic regression, and prognostic factors for relapse, DFS and overall survival were studied using the stepwise Cox proportional hazards model. All variables that were potentially (two-tailed P р 0.1 in the univariate analysis) predictive for acute GVHD occurrence, relapse or survival and their interactions were proposed for entry in the stepwise multivariate model for prediction of the same end point. Fit of the models was tested using the likelihood ratio statistics. All computations were made using BMDP software (BMDP Statistical Software, Los Angeles, CA, USA).
Results
Acute and chronic GVHD
Incidence and severity of acute GVHD among the two groups are reported in Table 2 . Acute GVHD developed in 49 patients of group I (79%, CI, 67-88%) and 81 patients of group II (71%, CI, 63-79%). However, acute GVHD was significantly more severe in group I than in group II, with 66% (CI, 53-78%) of all patients having grades II-IV GVHD in group I, vs 25% (CI, 17-33%) in group II (P Ͻ 0.0001). There was no significant difference between the two groups in delay of diagnosis of grade уII acute GVHD, although grade I was diagnosed significantly later in group I than in II (day 36 vs day 19, (P = 0.02).
Three patients in each group were not evaluated for response to GVHD therapy; five (three grade I, two grade II) were not treated and one (grade IV) died soon after the diagnosis of acute GVHD. When acute GVHD response to MP was analyzed in all evaluable patients developing GVHD regardless of grade, 61% (CI, 45-75%) of patients in group I and 80% (CI, 69-88%) in group II had a complete response (P = 0.006) ( Table 3) . One hundred and thirty-two patients, 41 in group I and 91 in group II, survived 3 months or more and were evaluable for the occurrence of chronic GVHD.
Incidence of chronic GVHD was significantly different between the two group 39% (CI, 24-55%) in group I and 30% (CI, 21-40%) in group II, (P = 0.04) and there were more cases of extensive chronic GVHD in group I (29%, CI, 16-45%) than in group II (11%, CI, 5-19%, P = 0.04).
In a multivariate analysis taking into account potentially contributing factors, the only factors related to occurrence of severe (grades II-IV) acute GVHD were standard GVHD management (group I) (P Ͻ 0.001) and increasing age (P Ͻ 0.001).
Other post-transplant complications
These included septicemia in 17 patients (27%, CI, 17-40%) in group I and 56 patients (48%, CI, 39-57%) in group II, and interstitial pneumonitis (IP) in 17 patients (27%, CI, 17-40%) in group I and 10 patients (9%, CI, 4-16%) in group II (P = 0.0007). The excess of IP observed in group I was not significantly related to the more frequent use of TBI in the conditioning regimen nor to more severe acute GVHD in this group. There was no significant difference in the incidence of veno-occlusive disease between the two groups.
Survival and disease-free survival
With a median follow-up of 57 months, 5-year DFS in the two groups is 50% (CI, 36-64%) and 46% (CI, 36-56%), respectively, while 5-year survival is 54% (CI, 42-66%) and 53% (CI, 43-63%), respectively, without significant differences between groups (Figure 1 ). However, actuarial risk of relapse at 5 years is 17% (CI, 4-30%) in group I compared to 36% (CI, 25-47%) in group II (P = 0.02) (Figure 2 ). The probability of survival was 49% (CI, 40-58%) in patients who developed acute GVHD compared to 68% (CI, 52-84%) in those who did not (P = 0.004) ( Figure  3 ). Despite different therapy of GVHD, there was no significant difference in survival between the two groups according to GVHD grading. Actuarial risk of relapse was 41% (CI, 25-57%) in patients without acute GVHD and 25% (CI, 15-35%) in patients who had acute GVHD (Figure 4) . Based on the results of univariate analysis, the type and stage of underlying hematologic malignancy, age of the patient, group of GVHD management and use of TBI in the conditioning regimen were proposed for entry into multivariate models for prediction of survival, DFS, and actuarial risk of relapse. Only advanced stage of underlying malignancy and increasing age were predictive for shorter survival (P Ͻ 0.001 and 0.04, respectively) and only increasing age was predictive for shorter DFS (P Ͻ 0.03). Actuarial risk of relapse was significantly higher in patients receiving intensive (group II) GVHD management (P = 0.04) and transplanted for a pathology other than CML (P = 0.07).
Discussion
Acute GVHD is still a frequent complication of allogeneic BMT. GVHD prophylaxis used in our study was MTX and CsA, which have been shown to be the most effective at decreasing incidence of acute GVHD. 1, 12 In our series, a GVHD incidence of 79% in group I and 71% in group II was higher than in several other trials, in which it varied between 30 and 70%. 1, 2, 12 We observed 66% of grades II-IV in group I and 25% in group II. Because of similar predictive risk factors for acute GVHD in the two groups, 13 the high dose of prophylactic CsA and high dose of steroids, which could have prevented evolution to more severe acute GVHD in group II, could explain the difference of acute GVHD severity between the two groups. Moreover, in multivariate analysis the more significant factor was GVHD management. The longer delay in diagnosis of grade I acute GVHD in group I by comparison to group II might be explained by different criteria for performing the confirmative biopsy rather than the different management of GVHD, since this longer delay is not observed in the more severe acute GVHD cases. Steroids remain the treatment of choice for acute GVHD and other agents have often been administered only for resistant disease. In our study, response rate to steroids was very high, especially in group II. Non-responsive acute GVHD was only observed in 22% of patients in group I and 9% in group II. When we analyzed response to MP according to GVHD grading, we observed no difference between groups I and II, suggesting that there was no relationship between the use of high-dose MP and resolution of severe GVHD. A wide range of steroid doses has been used as initial systemic treatment of acute GVHD. In studies using standard doses of steroids (2 mg/kg/day), the overall response rate ranged from 24% to 49% with 18-41% complete disappearance of GVHD. 4, 10, [14] [15] [16] Higher doses of steroids (more than 5 mg/kg/day) led to higher response rates. [17] [18] [19] However, in a study comparing various starting doses of MP, response rate was similar whatever the initial dose. 20 Toxicity of prolonged high doses of steroids is substantial, with frequent bacterial and fungal infections. 19 However, a study comparing short vs long tapering of steroid doses showed similar infectious complications. 21 In our study, there was a higher incidence of septicemia in the group receiving high-dose steroids. Some known risk factors for IP are long interval between diagnosis and transplant, conditioning with TBI and severe acute GVHD. 22 In our series, we found no relationship between the occurrence of IP and these previously described risk factors except for incidence of severe acute GVHD. Moreover, the higher dose of steroids received by patients in group II may have been protective against IP.
Many studies show that acute and chronic GVHD, particularly of low grades, is associated with a durable antileukemic effect. 9, [23] [24] [25] [26] In our study, survival and DFS of patients in the two groups were similar, probably because of the higher incidence of severe acute GVHD in group I. Analyzing the influence of acute GVHD on overall outcome, we confirmed a significant negative effect on survival and DFS, and observed a trend to lower actuarial risk of relapse in patients with acute GVHD. The survival advantage potentially conferred by a lower incidence of severe GVHD in group II was counterbalanced by the higher incidence of relapse in this group. Our study does not allow determination of whether use of higher prophylactic CsA doses or use of higher therapeutic MP doses plays the most important role in the higher relapse rate in group II, since these two approaches were associated. A randomized study has shown that a reduction in prophylactic CsA doses from 5 to 1 mg/kg/day, was associated with a decreased probability of relapse and longer DFS. 27 Overall, our study comparing two different managements of GVHD confirms that doses of cyclosporine and corticosteroid can influence the GVL effect after allogeneic BMT for hematologic malignancies.
However, the potential survival benefit of a decreased relapse rate is offset by GVHD-related lethal toxicity. This justifies new therapeutic approaches for treating acute GVHD using in vivo monoclonal antibodies. [28] [29] [30] [31] [32] [33] [34] and modulating the GVL effect. [35] [36] [37] [38] 
